BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 31200855)

  • 1. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
    Pettersson M; Crews CM
    Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROTACs: past, present and future.
    Li K; Crews CM
    Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
    Sincere NI; Anand K; Ashique S; Yang J; You C
    Molecules; 2023 May; 28(10):. PubMed ID: 37241755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications.
    Li Q; Zhou L; Qin S; Huang Z; Li B; Liu R; Yang M; Nice EC; Zhu H; Huang C
    Eur J Med Chem; 2023 Sep; 257():115447. PubMed ID: 37229829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
    Yang W; Saboo S; Zhou L; Askin S; Bak A
    Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
    Burslem GM; Crews CM
    Cell; 2020 Apr; 181(1):102-114. PubMed ID: 31955850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Studies of PROTACs in Hematological Malignancies.
    Fuchs O; Bokorova R
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontiers in PROTACs.
    Hughes GR; Dudey AP; Hemmings AM; Chantry A
    Drug Discov Today; 2021 Oct; 26(10):2377-2383. PubMed ID: 33872800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.
    Yokoo H; Naganuma M; Oba M; Demizu Y
    Chem Biodivers; 2022 Nov; 19(11):e202200828. PubMed ID: 36124821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.